This CPB is revised to state that bortezomib (Velcade) is considered medically necessary as single-agent therapy for relapsed or refractory primary cutaneous anaplastic large cell lymphoma (ALCL) with multifocal lesions; or for cutaneous ALCL with regional nodes. This CPB is revised to state that bortezomib (Velcade) for the following cancers is considered medically necessary for the following indications: 1) Adult T-cell leukemia/lymphoma - therapy for nonresponders to first-line therapy; 2) Multicentric Castleman's disease - as subsequent therapy with or without rituximab for disease that has progressed following treatment of relapsed/refractory or progressive disease; 3) Primary cutaneous anaplastic large cell lymphoma (ALCL) with multifocal lesions and cutaneous ALCL with regional nodes (excludes systemic ALCL) - single agent therapy for relapsed or refractory disease; 4) Angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma not otherwise specified, anaplastic large cell lymphoma, or enteropathy-associated T-cell lymphoma - second line or subsequent therapy when criteria are met; 5) Systemic light-chain amyloidosis - as a single agent or in combination with dexamethasone with or without melphalan or cyclophosphamide; and 6) Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma - as a single agent, in combination with dexamethasone, or in combination with rituximab (Rituxan) for primary therapy, progressive or relapsed disease or salvage therapy for disease that does not respond to primary therapy. This CPB is revised to state that bortezomib is considered experimental and investigational for primary cutaneous follicle center lymphoma, primary cutaneous marginal zone lymphoma, and mycosis fungoides/Sezary syndrome.